CA3065074A1 - Producing water soluble nano-emulsion particles containing cannabis/ cannabinoid oil or cannabis concentrate using ultrasonic processing technology and its use thereof in the beverage, edible powder and multipurpose cream - Google Patents
Producing water soluble nano-emulsion particles containing cannabis/ cannabinoid oil or cannabis concentrate using ultrasonic processing technology and its use thereof in the beverage, edible powder and multipurpose creamInfo
- Publication number
- CA3065074A1 CA3065074A1 CA3065074A CA3065074A CA3065074A1 CA 3065074 A1 CA3065074 A1 CA 3065074A1 CA 3065074 A CA3065074 A CA 3065074A CA 3065074 A CA3065074 A CA 3065074A CA 3065074 A1 CA3065074 A1 CA 3065074A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- oil
- cannabis
- present
- another object
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000218236 Cannabis Species 0.000 title description 61
- 229930003827 cannabinoid Natural products 0.000 title description 39
- 239000003557 cannabinoid Substances 0.000 title description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title description 25
- 239000002245 particle Substances 0.000 title description 20
- 239000006071 cream Substances 0.000 title description 13
- 239000000843 powder Substances 0.000 title description 11
- 239000007908 nanoemulsion Substances 0.000 title description 9
- 235000013361 beverage Nutrition 0.000 title description 7
- 239000012141 concentrate Substances 0.000 title description 2
- 239000000203 mixture Substances 0.000 description 160
- 229960004242 dronabinol Drugs 0.000 description 61
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 55
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 55
- 239000000839 emulsion Substances 0.000 description 50
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 45
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 45
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 45
- 229950011318 cannabidiol Drugs 0.000 description 45
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 45
- 150000003904 phospholipids Chemical group 0.000 description 37
- 239000003921 oil Substances 0.000 description 29
- 235000019198 oils Nutrition 0.000 description 29
- 229940065144 cannabinoids Drugs 0.000 description 26
- 238000000034 method Methods 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 17
- 230000000699 topical effect Effects 0.000 description 17
- 239000007787 solid Substances 0.000 description 16
- 235000013601 eggs Nutrition 0.000 description 15
- 235000012424 soybean oil Nutrition 0.000 description 15
- 235000019486 Sunflower oil Nutrition 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 239000002600 sunflower oil Substances 0.000 description 13
- 235000019482 Palm oil Nutrition 0.000 description 10
- 239000000828 canola oil Substances 0.000 description 10
- 235000019519 canola oil Nutrition 0.000 description 10
- 239000003240 coconut oil Substances 0.000 description 10
- 235000019864 coconut oil Nutrition 0.000 description 10
- 239000004006 olive oil Substances 0.000 description 10
- 235000008390 olive oil Nutrition 0.000 description 10
- 239000002540 palm oil Substances 0.000 description 10
- 239000003549 soybean oil Substances 0.000 description 10
- 125000005908 glyceryl ester group Chemical group 0.000 description 9
- 239000008173 hydrogenated soybean oil Substances 0.000 description 9
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 9
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 9
- 235000019477 peppermint oil Nutrition 0.000 description 9
- 239000010491 poppyseed oil Substances 0.000 description 9
- 235000003441 saturated fatty acids Nutrition 0.000 description 9
- 150000004671 saturated fatty acids Chemical class 0.000 description 9
- ZLYNXDIDWUWASO-UHFFFAOYSA-N 6,6,9-trimethyl-3-pentyl-8,10-dihydro-7h-benzo[c]chromene-1,9,10-triol Chemical compound CC1(C)OC2=CC(CCCCC)=CC(O)=C2C2=C1CCC(C)(O)C2O ZLYNXDIDWUWASO-UHFFFAOYSA-N 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000006196 drop Substances 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 239000002674 ointment Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 239000006188 syrup Substances 0.000 description 8
- 235000020357 syrup Nutrition 0.000 description 8
- 244000068988 Glycine max Species 0.000 description 7
- 235000010469 Glycine max Nutrition 0.000 description 7
- 239000007933 dermal patch Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000006072 paste Substances 0.000 description 7
- 239000006187 pill Substances 0.000 description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
- 229920000053 polysorbate 80 Polymers 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 241000251468 Actinopterygii Species 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000006193 liquid solution Substances 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- -1 oral Substances 0.000 description 6
- 238000009928 pasteurization Methods 0.000 description 6
- 244000144977 poultry Species 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 4
- RBEAVAMWZAJWOI-MTOHEIAKSA-N (5as,6s,9r,9ar)-6-methyl-3-pentyl-9-prop-1-en-2-yl-7,8,9,9a-tetrahydro-5ah-dibenzofuran-1,6-diol Chemical compound C1=2C(O)=CC(CCCCC)=CC=2O[C@H]2[C@@H]1[C@H](C(C)=C)CC[C@]2(C)O RBEAVAMWZAJWOI-MTOHEIAKSA-N 0.000 description 4
- TWKHUZXSTKISQC-UHFFFAOYSA-N 2-(5-methyl-2-prop-1-en-2-ylphenyl)-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1C1=CC(C)=CC=C1C(C)=C TWKHUZXSTKISQC-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 240000002791 Brassica napus Species 0.000 description 3
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000208818 Helianthus Species 0.000 description 3
- 235000003222 Helianthus annuus Nutrition 0.000 description 3
- 235000019484 Rapeseed oil Nutrition 0.000 description 3
- 239000002199 base oil Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 2
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- IGHTZQUIFGUJTG-QSMXQIJUSA-N O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 Chemical compound O1C2=CC(CCCCC)=CC(O)=C2[C@H]2C(C)(C)[C@@H]3[C@H]2[C@@]1(C)CC3 IGHTZQUIFGUJTG-QSMXQIJUSA-N 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 229960001462 sodium cyclamate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 description 1
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/02—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by the production or working-up
- A23D7/04—Working-up
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/003—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0053—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Description
Producing water soluble Nano-Emulsion particles containing Cannabis/
Cannabinoid oil or Cannabis concentrate using Ultrasonic processing technology and its use thereof in the beverage, edible powder and multipurpose cream Kind Code:
Al Abstract:
The present invention discloses a cannabis-based Nano-emulsion formulation for use in various beverage, edible powder and multipurpose cream with various compositions, wherein the oily fraction used contains about 0.5-5% cannabinoids. The present invention further discloses methods of manufacturing and uses of the afore mentioned composition.
Inventors:
Naserpour Farivar, Taghi (803; 3080 Lincoln Ave., Coquitlam, BC V3BOL9;
taghin(&yahoo.com; 604-657-6373) Assignee:
DR. Farivar Food Consulting LTD. (Vancouver, BC) Claims:
1. A composition of phospholipids or its derivatives, and an oily fraction, said composition is formulated as an emulsion; wherein said oily fraction contains about 0.5-5%
cannabinoids.
Cannabinoid oil or Cannabis concentrate using Ultrasonic processing technology and its use thereof in the beverage, edible powder and multipurpose cream Kind Code:
Al Abstract:
The present invention discloses a cannabis-based Nano-emulsion formulation for use in various beverage, edible powder and multipurpose cream with various compositions, wherein the oily fraction used contains about 0.5-5% cannabinoids. The present invention further discloses methods of manufacturing and uses of the afore mentioned composition.
Inventors:
Naserpour Farivar, Taghi (803; 3080 Lincoln Ave., Coquitlam, BC V3BOL9;
taghin(&yahoo.com; 604-657-6373) Assignee:
DR. Farivar Food Consulting LTD. (Vancouver, BC) Claims:
1. A composition of phospholipids or its derivatives, and an oily fraction, said composition is formulated as an emulsion; wherein said oily fraction contains about 0.5-5%
cannabinoids.
2. The composition of claim 1, wherein said composition comprises Nano size particles in a diameter less than 200 nm and preferably <50nm( Passing through 0.2 gm=200nm filter)
3. The composition of claim 2, wherein said particles diameter less than 200 nm and preferably <50nm (Passing through 0.2 gm=200nm filter).
4. The composition of first claim, in which the composition is administered in the following ways;
Oral, rectal, Vaginal, topical and any combination of them.
Oral, rectal, Vaginal, topical and any combination of them.
5. The composition of first claim, comprises various molecules specifically fatty molecules, without sediments or any solid particles.
6. The composition of first claim in which the composition is formulated in a dosage form the following ways: liquid, solid, oral, pill, capsule, sub-lingual, orally-disintegrating, liquid solution, powder or liquid or solid, pastes, syrup, topical, cream, gel, lotion, ointment, drops, skin patch, vaginal, and any combination of them.
7. The composition of first claim in which at least one of the following is true: a. said composition contains at least one cannabinoid; b. said composition contained predetermined ratio of said cannabinoids; c. said cannabinoid is extracted from cannabis plant, cannabinoids with
8. The composition according to claim 7, wherein at least one of the following is true: a. the THC
or a derivative thereof and any combination thereof; b. the Cannabidiol (CBD) or a derivative thereof and any combination thereof; c. said THC or a derivative thereof is selected from the group of natural THC or its derivative extracted from plants, synthetic THC or a derivative thereof, and any combination of them ; and d. CBD or its derivative is natural CBD or its derivative extracted from plants, synthetic CBD or a derivative of it, and any combination of them.
or a derivative thereof and any combination thereof; b. the Cannabidiol (CBD) or a derivative thereof and any combination thereof; c. said THC or a derivative thereof is selected from the group of natural THC or its derivative extracted from plants, synthetic THC or a derivative thereof, and any combination of them ; and d. CBD or its derivative is natural CBD or its derivative extracted from plants, synthetic CBD or a derivative of it, and any combination of them.
9. The composition of first claim in which at least one of the following is true: a. said the composition contained Tetrahydrocannabinol (THC) and/ or Cannabidiol (CBD), or an extract comprising said Tetrahydrocannabinol (THC) and/ or Cannabidiol (CBD); b. said composition is configured to be pasteurize at the ranges from 57 to 68 C with a holding time of 15-30 s or 63-65 C for 15 s or 65 C for 20 s.; c. said composition comprises about 0.5-5%%
cannabis oil; d. said composition comprises an oily phase and a water phase in a ratio of about 1.5-15% to about 98.5-85%, respectively;
cannabis oil; d. said composition comprises an oily phase and a water phase in a ratio of about 1.5-15% to about 98.5-85%, respectively;
10. The composition of claim 9 wherein said cannabis is cannabis oil, said surfactant is phospholipids or tween 80 or any combination thereof.
11. The composition of claim any one of claims 1 and 10, wherein at least one of the following holds true: a. said cannabinoids are cannabidiol (CBD) or its derivative, Tetrahydrocannabinol (THC) or its derivatives, and any combination of the; b. final concentration of said THC or a derivative thereof, in said emulsion is in the range of about 5 to about 50 mg/ml; c. a single dose of about 0.5 ml of said cannabis emulsion contains a dose of about 10 mg THC;
d. the ratio of said oily fraction and said phospholipid is between 4:1 and 12:1; e. said oily fraction is in the range of about 1.5% to about 15%; and f. said oily fraction is in the range of about 1.5% to about 15%.
d. the ratio of said oily fraction and said phospholipid is between 4:1 and 12:1; e. said oily fraction is in the range of about 1.5% to about 15%; and f. said oily fraction is in the range of about 1.5% to about 15%.
12. The composition of first claim in which at least one of the following is true: a. said oily fraction is selected from the group consisting of cannabis oil, coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination thereof; b. phospholipids or its derivatives are natural food sources like eggs, cattle milk, fish eggs, sunflower oil, soya oil, rapeseed oil, poultry and any combination of them or phospholipids or its derivative have a synthetic route; c. said composition is stable under pasteurization process at 57 to 68 C with a holding time of 15-30 s or a treatment of 63-65 C for 15 s or 65 C for 20 s;
d. said composition is administered once, twice, three or four times through the day; e. said oily fraction is cannabis oil obtained from at least one cannabis plant; f. said CBD or derivative thereof is produced by a synthetic route; and g. said THC or derivative thereof is produced by a synthetic route.
d. said composition is administered once, twice, three or four times through the day; e. said oily fraction is cannabis oil obtained from at least one cannabis plant; f. said CBD or derivative thereof is produced by a synthetic route; and g. said THC or derivative thereof is produced by a synthetic route.
13. The composition of first claim in which at least one of the following is true:
a. composition also may contains an additional lipophilic solvent or suspension carrier; b. said lipophilic solvent or suspension carrier are selected from a group consisting of Carrier oil which is a long-chain triglyceride(LCT) such as coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination thereof; c.
said composition further comprising powdering or flavoring agents, selected from the group consisting of sugar, sucrose, sorbitol, sucralose, saccharin sodium, sodium cyclamate, aspartame, stevioside, sodium chloride, D-limonene, citric acid, and any combination thereof;
a. composition also may contains an additional lipophilic solvent or suspension carrier; b. said lipophilic solvent or suspension carrier are selected from a group consisting of Carrier oil which is a long-chain triglyceride(LCT) such as coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination thereof; c.
said composition further comprising powdering or flavoring agents, selected from the group consisting of sugar, sucrose, sorbitol, sucralose, saccharin sodium, sodium cyclamate, aspartame, stevioside, sodium chloride, D-limonene, citric acid, and any combination thereof;
14. The composition according first claim in which the composition is prepared by the following steps: a. combining phospholipids or its derivatives with an oily fraction and obtaining an oily phase; b. combining said oily phase with a water phase in and transferring into a Ultra-sound probe containing container, thereby obtaining a cannabis composition in the formulation of an emulsion; further wherein said oily fraction contains about 0.5-5%
cannabinoids.
cannabinoids.
15. The composition according to claim 14, comprising steps of: a. preparing an Oil phase by mixing cannabis oil, soya phospholipids and Polysorbate 80 and Soya oil ; b.
adding the water phase to the oil phase; c. preparation of an emulsion from said mixture of step b with Ultrasounic processor unit with high amplitude (901.ipp) in a batch or continues flow cell at room temperature and optionally, sterilizing said emulsion.
adding the water phase to the oil phase; c. preparation of an emulsion from said mixture of step b with Ultrasounic processor unit with high amplitude (901.ipp) in a batch or continues flow cell at room temperature and optionally, sterilizing said emulsion.
16. A method of using claim 15 in producing cold and hot beverage by adding suitable volume to have a 10 mg in a portion of a beverage., said composition is formulated as an emulsion, wherein said oily fraction contains about 0.5-5% cannabinoids.
17. A method of using claim 15 in powdering or flavoring agents, selected from the group consisting of sugar, sucrose, sorbitol, sucralose, saccharin sodium, sodium cyclamate, aspartame, stevioside, sodium chloride, D-limonene, citric acid, and any combination thereof said composition is formulated as an emulsion, wherein said oily fraction contains about 0.5-5%
cannabinoids.
cannabinoids.
18. A method of using claim 15 in producing a water base multi-purpose lubricant or cream, said composition is formulated as an emulsion, wherein said oily fraction contains about 0.5-5%
cannabinoids.
FIELD OF THE INVENTION
The present disclosure relates to novel compositions and methods for making water soluble Nano-emulsion containing enriched concentrations of Tetrahydrocannabinol (THC), cannabidiol (CBD) or derivatives using Ultrasonic processing technology. More particularly the current invention pertains to an emulsion comprising thereof, useful for application in beverage industries, edible powder and multi purpose cream or lubricant.
BACKGROUND OF THE INVENTION
Cannabinoids are produced in Cannabis plant and when they consumed they produce mental and physical effects. Two of the most important cannabinoids are Tetrahydrocannabinol (THC) and Cannabidiol (CBD).
CBD and THC are highly lipophilic molecules and are essentially water insoluble and so are difficult to formulate in relatively high concentration in beverages and specially water- base beverages, without having to increase the oily fraction.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a composition containing phospholipids or its derivatives and an oily fraction. This composition is formulated as an emulsion, wherein the oily fraction contains about 0.5-5% cannabinoids. It is also another object of the present invention to provide the composition as defined in any of the above claims in which this composition comprises small-size particles in a diameter range <50 nm It is also another object of the present invention to provide the composition as defined in any of the above, wherein said particles diameter less than 200 nm and preferably <50nm ( Passing through 0.2 gm=200nm filter).
The composition of first claim in which the composition is administered by the following ways:
Oral, rectal, Vaginal, topical and any combination of them.
The composition according to the first claim in which the composition is formulated in a dosage form selected from the group consisting of liquid, solid, oral, pill, capsule, sub-lingual, orally-disintegrating, liquid solution, powder or liquid or solid, pastes, syrup, topical, cream, gel, lotion, ointment, drops, skin patch, vaginal, and any combination thereof.
It is also another object of the present invention to provide the composition as defined in any of the above claims, wherein said composition comprises a variety of molecules specifically fatty molecules, without sediments or any solid particles.
It is also another object of the present invention to provide the composition as defined in any of the above claims in which the composition comprises predetermined ratio of said cannabinoids.
It is also another object of the present invention to provide the composition as defined in any of the above claims, in which the cannabinoid is cannabinoid-type, cannabinoid derivative, cannabis extract or fraction of them and any combination of them.
It is also another object of the present invention to provide the composition as defined in any of the above claims in which the cannabinoid is selected from a. the THC or its derivative and any combination of them; b. the cannabidiol (CBD) or its derivative and any combination of them; c.
THC or its derivative is natural THC or its derivative extracted from plants, synthetic THC or its derivative and any combination of them; and d. CBD or its derivative is natural CBD which extracted from plants, synthetic CBD or its derivative and any combination of them.
It is also another object of the present invention to provide the composition as defined in any of the above claims in which the composition is stable under pasteurization process at 57 to 68 C
with a holding time of 15-30 s or a treatment of 63-65 C for 15 s or 65 C for 20 s.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein said composition comprises about 1.5-15% cannabis oil.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein said composition comprises an oily phase and a water phase in a ratio of about 1.5-15% to about 98.5-85%, respectively.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein said oily phase comprises about 4:1 to 12:1 of phospholipids.
It is also another object of the present invention to provide the composition as defined in any of the above wherein said composition comprises cannabis, surfactant, glycerol and water.
It is also another object of the present invention to provide the composition as defined in any of the above wherein said cannabis is cannabis oil; said surfactant is phospholipids or tween 80 or any combination thereof.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein said oily phase comprises cannabis oil, egg phospholipids, soya phospholipids and wherein said water phase comprises water.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein at least one of the following holds true: a. said emulsion is with a particle diameter in the range of about <50 nm and b. said emulsion prepared in sterile environment is with a particle diameter of about <50 nm.
It is also another object of the present invention to provide the composition as defined in any of the above claims in which at least one of the following is true: a. said cannabinoids are selected from: Cannabigerol (CBG) type, Cannabichromene (CBC) type, Cannabidiol (CBD) type, A9-Tetrahydrocannabinol (THC) type, A8-THC type, Cannabicyclol (CBL) type, Cannabielsoin (CBE) type, Cannabinol (CBN) and Cannabinodiol (CBND) types, Cannabitriol (CBT) type; b.
final concentration of THC or its derivative, in the emulsion is in the range of 10- 50 mg/ml; c. a single dose of said cannabis emulsion contains a dose of about 10 mg THC; d.
the ratio of said oily fraction and said phospholipid is between 4:1 and 12:1; e. oily fraction is in the range of 5% - 50%;
and f. said oily fraction is in the range of about 1.5-15%.
It is also another object of the present invention to provide the composition as defined in any of the above claims, wherein at least one of the following is true: a. said oily fraction is selected from the group consisting of coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination thereof; b. phospholipids or its derivatives are natural food sources like eggs, cattle milk, fish eggs, sunflower oil, soya oil, rapeseed oil, poultry and any combination of them or phospholipids or its derivative have a synthetic route.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein at least the following holds true: particle size of said emulsion is in the range of about <50 nm.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein at least one of the following holds true: a. The composition of first claim in which the composition is administered by the following ways: Oral, rectal, Vaginal, topical and any combination thereof. b. The composition according to first claim in which the composition is formulated in a dosage form selected from the group consisting of liquid, solid, oral, pill, capsule, sub-lingual, orally-disintegrating, liquid solution, powder or liquid or solid, pastes, syrup, topical, cream, gel, lotion, ointment, drops, skin patch, vaginal, and any combination thereof It is also another object of the present invention to provide the composition as defined in any of the above claims, wherein at least one of the following is true: a. mentioned oily fraction is cannabis oil extracted from cannabis plant; b. CBD or its derivative is produced by a synthetic route; and c. used THC or its derivative is produced by a synthetic route.
It is also another object of the present invention to provide the composition as defined in any of the above claims in which cannabis plant is a CBD or THC rich strain.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein at least one of the following holds true: a. said composition is formulated for administration of 10 mg THC per dosage unit; b. mentioned composition containes an additional lipophilic solvent or suspension carrier; c. said lipophilic solvent or suspension Carrier oil is a long-chain triglyceride(LCT) such as coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination thereof, and any combination thereof;
It is also another object of the present invention to provide the composition as defined in any of the above claims in which at least one of the following is true: a. said composition comprises predetermined ratio of said cannabinoids; b. said cannabinoid is extracted from cannabis plant; c.
mentioned cannabinoid is selected from cannabinoid derivative or cannabis extract or fraction of that and any combination of that; and d. said cannabinoid is selected from the group consisting of:
Cannabigerol (CBG) type, annabichromene (CBC) type, Cannabidiol (CBD) type, A9-Tetrahydrocannabinol (THC) type, A8-THC type, Cannabicyclol (CBL) type, Cannabielsoin (CBE) type, Cannabinol (CBN) and Cannabinodiol (CBND) types, Cannabitriol (CBT) typeand any combination thereof.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein at least one of the following holds true: a. said composition is stable under pasteurization process at 57 to 68 C with a holding time of 15-30 s or a treatment of 63-65 C for 15 s or 65 C for 20 s.; b. said composition comprises about 0.5-5% Cannabis oil; c. said composition comprises an oily phase and a water phase in a ratio of about 1.5%-15% to about 98.5- 85%, respectively; d. said oily phase comprises about 4:1 to 12:1 phospholipid and said composition comprises cannabis, surfactant, carrier oil, and e. said oily phase comprises cannabis oil, egg phospholipids, soya phospholipids and wherein said water phase comprises of water.
It is also another object of the present invention to provide the composition as defined in any of the above wherein said cannabis is cannabis oil; said surfactant is phospholipids or tween 80 or any combination thereof.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein at least one of the following holds true: a. said cannabinoids are from cannabidiol (CBD) or its derivative, Tetrahydrocannabinol (THC) or its derivative, and any combination of that; b. final concentration of mentioned THC or its derivative, in the emulsion is 80- 100 mg/ml; c. a single dose of about 0.5 ml of cannabis emulsion contains a dose of about 12 to about 15 mg THC; d. the ratio of mentioned oily fraction and mentioned phospholipid is between 4:1 and 12:1; e. mentioned oily fraction is 5%- 50%; and f. said oily fraction is in the range of about 1.5-15%.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein at least one of the following is true: a. mentioned oily fraction is from cannabis oil, borage oil, coconut oil, cottonseed oil, soybean oil, safflower oil, sunflower oil, corn oil, olive oil, palm oil, peanut oil, canola oil, and any combination thereof; b.
mentioned phospholipids, or its derivatives are derived from a naturally originated food sources from soya , rapeseed, sunflower, cattle milk, fish eggs, poultry eggs and any combination of that;
c. said phospholipids, or derivative thereof, are produced by a synthetic route; d. said composition is stable under pasteurization process at 57 to 68 C with a holding time of 15-30 s or a treatment of 63-65 C for 15 s or 65 C for 20 s It is also another object of the present invention to provide the composition as defined in any of the above claims, wherein said composition is prepared by the steps of: a.
combining phospholipids or its derivatives and an oily fraction and obtaining an oily phase; b. mixing oily and water phases in an ultrasonicator and obtaining pre-emulsion; and c. transferring pre-emulsion into a ultrasonicator and obtaining a cannabis composition in the formulation of an emulsion; further wherein said oily fraction contains about 0.5-5% cannabinoids.
It is also another object of the present invention to provide the composition as defined in any of the above, further prepared by steps of: a. preparing an oil phase by mixing cannabis oil, soya phospholipids, polysorbate 80 and Lecithin; b. preparing a water phase c.
adding the water phase to the oil phase d. preparation of an emulsion from said mixture of step c with Ultrasonicator at 90% amplitude for 20 min in a cold-water bath or in a reaction chamber with a cooling jacket; e.
optionally, sterilizing produced emulsion.
It is also another object of the present invention to provide the use as defined in any of the above claims in which composition comprises small-size particles in a diameter less than 200 nm and preferably <50nm ( Passing through 0.2 ilm=200nm filter), It is also another object of the present invention to provide the use as defined in any of the above, wherein said composition comprises about 0.5-5% cannabis oil.
It is also another object of the present invention to provide the use as defined in any of the above, wherein said a. the composition is administered in a manner selected from the group consisting of:
sublingual, transdermal, oromucosal, rectal, Vaginal, oral, topical and any combination thereof. b.
The composition is formulated in a dosage form from oral, pill, capsule, powder or liquid or solid, pastes, syrup, topical, cream, gel, lotion, ointment, drops, skin patch, vaginal, and any combination of that.
It is also an object of the present invention to provide the composition as mentioned above, wherein final concentration of the THC or a derivative thereof, in the emulsion is about 10-50 mg/ml.
It is also another object of the present invention to provide the composition as mentioned above, wherein a single dose of about 0.5 ml of the cannabis emulsion contains a dose of about 10 mg THC.
It is also another object of the present invention to provide the composition as mentioned above, wherein the ratio of the oily fraction and the phospholipid is between 4:1 and 12:1.
It is also an object of the present invention to provide the composition as mentioned above, wherein the oily fraction is in the range of about 1.5% to about 15%.
It is also another object of the present invention to provide the composition as mentioned above, wherein the oily fraction is selected from the group consisting of cannabis oil, coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination thereof.
It is also another object of the present invention to provide the composition as mentioned above, wherein the phospholipids or its derivatives are natural food sources like eggs, cattle milk, fish eggs, sunflower oil, soya oil, rapeseed oil, poultry and any combination of them.
It is also another object of the present invention to provide the composition as mentioned above, wherein the average particle size of the emulsion is in the range of about <50 nm.
It is also another object of the present invention to provide the composition as mentioned above, wherein the composition is stable under pasteurization process at 57 to 68 C
with a holding time of 15-30 s or a treatment of 63-65 C for 15 s or 65 C for 20 s.
It is also another object of the present invention to provide the composition as mentioned above, wherein the composition is to be administered in a route selected from a group consisting of:
transdermal, oral, topical, topical and any combination thereof.
It is also another object of the present invention to provide a composition as said above, wherein the composition is administered in a manner selected from the group consisting of: sublingual, transdermal, oromucosal, rectal, Vaginal, oral, topical and any combination thereof.
It is also another object of the present invention to provide the composition as mentioned above, wherein the composition is formulated in a dosage form liquid, solid, oral, pill, capsule, sub-lingual, orally-disintegrating, liquid solution, powder or liquid or solid , pastes, syrup, topical, cream, gel, lotion, ointment, drops, skin patch, vaginal, and any combination thereof.
It is also another object of the present invention to provide the composition as mentioned above, wherein the lipophilic solvent or suspension carrier are selected from a group consisting of long-chain triglyceride(LCT) such as coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination thereof;
It is another object of the present invention to disclose a composition prepared by combining phospholipids or its derivatives and an oily fraction for obtaining an oily phase; combining the oily phase with a water phase in an Nano emulsifier, for obtaining pre-emulsion; and transferring the pre-emulsion into a ultrasonicator for obtaining a cannabis composition in the formulation of an emulsion in which the oily fraction contains about 0.5-5% cannabinoids.
It is also another object of the present invention to provide the preparation method as mentioned above in which the cannabinoids are from: Cannabidiol (CBD) type or its derivatives or A9-Tetrahydrocannabinol (THC) type or its derivatives It is also an object of the present invention to provide the preparation method as mentioned above, wherein final concentration of the THC or a derivative thereof, in the emulsion is about 5-50 mg/ml.
It is also another object of the present invention to provide the preparation method as mentioned above in which a single dose of about 0.5 ml the cannabis emulsion contains a dose of about 10 mg THC.
It is also another object of the present invention to provide the preparation method as mentioned above in which the ratio of the oily fraction and the phospholipid is between 8:1 and 12:1.
It is also another object of the present invention to provide the preparation method as mentioned above for providing the composition with oily fraction in the range of 5%-50%.
It is also another object of the present invention to provide the preparation method as mentioned above, wherein the step uses a Ultra sonic Nano emulsifier having a power of 100-3000 W and 90% amplitude for 30 min, thereby resulting in an average particle size of the emulsion in the range of about <50 nm.
It is also another object of the present invention to provide the preparation method as mentioned above for sterilizing the cannabis composition.
It is also another object of the present invention to provide the preparation method as mentioned above, additionally comprising steps of formulating the composition to be stable under pasteurization process at 57 to 68 C with a holding time of 15-30 s or a treatment of 63-65 C for 15 s or 65 C for 20 s.
It is also another object of the present invention to provide the preparation method as mentioned above, additionally comprising steps of formulating the cannabis composition is administered in a manner selected from the group consisting of: sublingual, transdermal, oromucosal, rectal, Vaginal, oral, topical and any combination thereof.
It is also another object of the present invention to provide the preparation method as mentioned above, additionally comprising steps of formulating the cannabis composition is formulated in a dosage form selected from the group consisting of liquid, solid, oral, pill, capsule, sub-lingual, orally-disintegrating, liquid solution, powder or liquid or solid , pastes, syrup, topical, cream, gel, lotion, ointment, drops, skin patch, vaginal, and any combination thereof.
It is also another object of the present invention to provide the preparation method as mentioned above in which the oily fraction is cannabis oil obtained from a cannabis plant.
It is also another object of the present invention to provide the preparation method as mentioned above for formulating the cannabis composition for administration of about 5 mg- 15 mg THC per dosage unit.
It is also another object of the present invention to provide the preparation method as mentioned above for formulating the cannabis composition to contain an additional lipophilic solvent or suspension carrier.
It is also another object of the present invention to disclose the aforementioned method, wherein the cannabinoids are from: Cannabidiol (CBD) type or its derivatives or A9-Tetrahydrocannabinol (THC) type r its derivatives.
It is also another object of the present invention to disclose the aforementioned method for administering the composition with a final concentration of the THC or a derivative of that, in the emulsion of about 10 mg/ml.
It is also another object of the present invention to disclose the aforementioned method for administering the composition in a single dose of about 0.5 ml the cannabis emulsion containing a dose of about 10 mg THC.
It is also another object of the present invention to disclose the aforementioned method, additionally comprising steps of providing the composition with oily fraction is in the range of about 1.5% to about 15%.
It is also another object of the present invention to disclose the aforementioned method for providing the composition with oily fraction is in the range of about 10%-30%.
It is also another object of the present invention to disclose the aforementioned method for providing the composition wherein the oily fraction is from cannabis oil, coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination thereof.
It is also another object of the present invention to disclose the aforementioned method in which the phospholipids or its derivatives are derived from a natural food sources from poultry eggs, soya, rapeseed, sunflower, cattle milk, fish eggs and any combination thereof.
It is also another object of the present invention to disclose the aforementioned method in which the phospholipids, or its derivatives are derived by a synthetic route.
It is also another object of the present invention to disclose the aforementioned method, wherein the average particle size of the emulsion is in the range of about <50 nm.
It is also another object of the present invention to disclose the aforementioned method for administering the composition in the following manner: sublingual, transdermal, oromucosal, rectal, Vaginal, oral, topical and any combination of that.
It is also an object of the present invention to disclose the aforementioned method for administering the composition is formulated in a dosage form liquid, solid, oral, pill, capsule, sub-lingual, orally-disintegrating, liquid solution, powder or liquid or solid , pastes, syrup, topical, cream, gel, lotion, ointment, drops, skin patch, vaginal, and any combination thereof.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
It is understood that other examples may be used and structural changes may be made in within the scope of the present invention. The present invention may be performed according to the claims without some or all of these specific details.
The principle of the present invention is to provide a composition containing oil and phospholipids as an emulsion and useful for human, having used an oily fraction containing about 0.5-15%
cannabinoids. Such cannabinoids may be either cannabidiol (CBD) and/or Tetrahydrocannabinol (THC) or an extract of them. More specifically the present invention declaims a composition containing cannabinoids enhanced emulsions for either topical or oral use.
The term "cannabidiol (CBD)" refers to cannabinoids identified in cannabis.
The term "Tetrahydrocannabinol (THC)" refers to the principal psychoactive cannabinoid of the cannabis plant.
The term "particle size" refers to oil in water droplet diameter, or water in oil droplet diameter, in an emulsion.
The term "room temperature" refers to 20-25 Celsius degrees.
The term "fridge temperature" refers to 2-8 Celsius degrees.
The term "stable" refers to the stability of the emulsion.
It is another object of the present invention to disclose a cannabis emulsion composition containing phospholipids or its derivatives and an oily fraction, wherein the oily fraction is enriched and contains about 0.5-5% cannabinoids. Such cannabinoids may be from cannabidiol (CBD) or its derivative, Tetrahydrocannabinol (THC) or its derivative, and any combination of them.
In preferred embodiments, the Nano emulsion composition is provided with a lower viscosity.
In preferred embodiments, the Nano-emulsion composition is useful for transferring variety of molecules specifically fatty molecules, without sediments or any solid particles.
In preferred embodiments, the final concentration of THC or its derivative in the emulsion is 5-50 mg/ml. Thus, a 0.5 ml dose of the cannabis emulsion, contains a dose of about 10 mg THC.
It is in the scope of this invention to provide a composition as defined in any of the above claims in which the ratio of the oily fraction and the phospholipid is between 4:1 and 12:1.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the oily fraction is in the range of about 5% to about 15%.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the oily fraction may be from the group consisting of cannabis oil coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination of them.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the phospholipids are from natural food sources such as, poultry eggs, soya, rapeseed, sunflower, cattle milk, fish eggs and any combination thereof. In other embodiments, the phospholipids, or derivative of that have a synthetic route.
The composition as provided in the present invention may be manufactured to provide emulsion particle sizes in the range of about <50 nm. Such particularly small particle size is achieved through using a ultrasonicator having a power of 100-3000 Wats, 90% amplitude.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the composition is for oral administration in a formulation selected from a group of preparations consisting of syrup, drops, solution, suspension, tablet, capsule and any combination thereof.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the composition is for topical administration from the following ways: cream, ointment lotion, foam, transdermal patch and any combination thereof.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the composition is formulated for administration of 5 mg-15 mg THC per dosage unit.
It is further in the scope of this invention to provide additional lipophilic solvent or suspension carrier, which may be in a non-limiting example, long-chain triglyceride(LCT) such as coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination of them;
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the THC or its derivative is from THC or its derivatives and any combination of that.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the THC or its derivatives is extracted from cannabis.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the composition contains least one additional cannabinoid or a derivative of that.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the Cannabidiol (CBD) or a derivative of that is from CBD or its derivatives and any combination of them.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the CBD or its derivatives are extracted from cannabis.
In order to understand the invention and to see how it may be implemented in practice, a number of preferred examples which is not limited to these examples will now be described:
Example 1 Proposed Emulsion Composition: Cannabis oil :2g; Egg phospholipid: 3g;
Polysorbate80: 3g;
Soya oil: 3g; Purified water up to 100m1 Equipment: A Ultrasonicate device set on Amplitude: 90% with 400W power for 20 min.
Example 2 Protocol for Preparation of Cannabis Emulsion Emulsion Composition: Cannabis oil compositions containing THC and CBD in predetermined ratios; Surfactant: phospholipids and/or tween 80 and/or others; Lecithin;
Purified water Manufacturing Flow Chart:
Pre-Emulsion: Generating a Pre-Emulsion containing Oily and Water phases.
Nano-Emulsion: The resulting Pre-Emulsion is then undergone ultrasonication process in order to create a Nano-Emulsion;
Sterilization and confirmation of Nano sized particle: The resulting Nano-Emulsion is then passed through a 0.2 p,m filter resulting in the Sterilization of the Emulsion which confirms Nano size of the product (Filter pore size is 200 nm).
,
cannabinoids.
FIELD OF THE INVENTION
The present disclosure relates to novel compositions and methods for making water soluble Nano-emulsion containing enriched concentrations of Tetrahydrocannabinol (THC), cannabidiol (CBD) or derivatives using Ultrasonic processing technology. More particularly the current invention pertains to an emulsion comprising thereof, useful for application in beverage industries, edible powder and multi purpose cream or lubricant.
BACKGROUND OF THE INVENTION
Cannabinoids are produced in Cannabis plant and when they consumed they produce mental and physical effects. Two of the most important cannabinoids are Tetrahydrocannabinol (THC) and Cannabidiol (CBD).
CBD and THC are highly lipophilic molecules and are essentially water insoluble and so are difficult to formulate in relatively high concentration in beverages and specially water- base beverages, without having to increase the oily fraction.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a composition containing phospholipids or its derivatives and an oily fraction. This composition is formulated as an emulsion, wherein the oily fraction contains about 0.5-5% cannabinoids. It is also another object of the present invention to provide the composition as defined in any of the above claims in which this composition comprises small-size particles in a diameter range <50 nm It is also another object of the present invention to provide the composition as defined in any of the above, wherein said particles diameter less than 200 nm and preferably <50nm ( Passing through 0.2 gm=200nm filter).
The composition of first claim in which the composition is administered by the following ways:
Oral, rectal, Vaginal, topical and any combination of them.
The composition according to the first claim in which the composition is formulated in a dosage form selected from the group consisting of liquid, solid, oral, pill, capsule, sub-lingual, orally-disintegrating, liquid solution, powder or liquid or solid, pastes, syrup, topical, cream, gel, lotion, ointment, drops, skin patch, vaginal, and any combination thereof.
It is also another object of the present invention to provide the composition as defined in any of the above claims, wherein said composition comprises a variety of molecules specifically fatty molecules, without sediments or any solid particles.
It is also another object of the present invention to provide the composition as defined in any of the above claims in which the composition comprises predetermined ratio of said cannabinoids.
It is also another object of the present invention to provide the composition as defined in any of the above claims, in which the cannabinoid is cannabinoid-type, cannabinoid derivative, cannabis extract or fraction of them and any combination of them.
It is also another object of the present invention to provide the composition as defined in any of the above claims in which the cannabinoid is selected from a. the THC or its derivative and any combination of them; b. the cannabidiol (CBD) or its derivative and any combination of them; c.
THC or its derivative is natural THC or its derivative extracted from plants, synthetic THC or its derivative and any combination of them; and d. CBD or its derivative is natural CBD which extracted from plants, synthetic CBD or its derivative and any combination of them.
It is also another object of the present invention to provide the composition as defined in any of the above claims in which the composition is stable under pasteurization process at 57 to 68 C
with a holding time of 15-30 s or a treatment of 63-65 C for 15 s or 65 C for 20 s.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein said composition comprises about 1.5-15% cannabis oil.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein said composition comprises an oily phase and a water phase in a ratio of about 1.5-15% to about 98.5-85%, respectively.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein said oily phase comprises about 4:1 to 12:1 of phospholipids.
It is also another object of the present invention to provide the composition as defined in any of the above wherein said composition comprises cannabis, surfactant, glycerol and water.
It is also another object of the present invention to provide the composition as defined in any of the above wherein said cannabis is cannabis oil; said surfactant is phospholipids or tween 80 or any combination thereof.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein said oily phase comprises cannabis oil, egg phospholipids, soya phospholipids and wherein said water phase comprises water.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein at least one of the following holds true: a. said emulsion is with a particle diameter in the range of about <50 nm and b. said emulsion prepared in sterile environment is with a particle diameter of about <50 nm.
It is also another object of the present invention to provide the composition as defined in any of the above claims in which at least one of the following is true: a. said cannabinoids are selected from: Cannabigerol (CBG) type, Cannabichromene (CBC) type, Cannabidiol (CBD) type, A9-Tetrahydrocannabinol (THC) type, A8-THC type, Cannabicyclol (CBL) type, Cannabielsoin (CBE) type, Cannabinol (CBN) and Cannabinodiol (CBND) types, Cannabitriol (CBT) type; b.
final concentration of THC or its derivative, in the emulsion is in the range of 10- 50 mg/ml; c. a single dose of said cannabis emulsion contains a dose of about 10 mg THC; d.
the ratio of said oily fraction and said phospholipid is between 4:1 and 12:1; e. oily fraction is in the range of 5% - 50%;
and f. said oily fraction is in the range of about 1.5-15%.
It is also another object of the present invention to provide the composition as defined in any of the above claims, wherein at least one of the following is true: a. said oily fraction is selected from the group consisting of coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination thereof; b. phospholipids or its derivatives are natural food sources like eggs, cattle milk, fish eggs, sunflower oil, soya oil, rapeseed oil, poultry and any combination of them or phospholipids or its derivative have a synthetic route.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein at least the following holds true: particle size of said emulsion is in the range of about <50 nm.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein at least one of the following holds true: a. The composition of first claim in which the composition is administered by the following ways: Oral, rectal, Vaginal, topical and any combination thereof. b. The composition according to first claim in which the composition is formulated in a dosage form selected from the group consisting of liquid, solid, oral, pill, capsule, sub-lingual, orally-disintegrating, liquid solution, powder or liquid or solid, pastes, syrup, topical, cream, gel, lotion, ointment, drops, skin patch, vaginal, and any combination thereof It is also another object of the present invention to provide the composition as defined in any of the above claims, wherein at least one of the following is true: a. mentioned oily fraction is cannabis oil extracted from cannabis plant; b. CBD or its derivative is produced by a synthetic route; and c. used THC or its derivative is produced by a synthetic route.
It is also another object of the present invention to provide the composition as defined in any of the above claims in which cannabis plant is a CBD or THC rich strain.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein at least one of the following holds true: a. said composition is formulated for administration of 10 mg THC per dosage unit; b. mentioned composition containes an additional lipophilic solvent or suspension carrier; c. said lipophilic solvent or suspension Carrier oil is a long-chain triglyceride(LCT) such as coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination thereof, and any combination thereof;
It is also another object of the present invention to provide the composition as defined in any of the above claims in which at least one of the following is true: a. said composition comprises predetermined ratio of said cannabinoids; b. said cannabinoid is extracted from cannabis plant; c.
mentioned cannabinoid is selected from cannabinoid derivative or cannabis extract or fraction of that and any combination of that; and d. said cannabinoid is selected from the group consisting of:
Cannabigerol (CBG) type, annabichromene (CBC) type, Cannabidiol (CBD) type, A9-Tetrahydrocannabinol (THC) type, A8-THC type, Cannabicyclol (CBL) type, Cannabielsoin (CBE) type, Cannabinol (CBN) and Cannabinodiol (CBND) types, Cannabitriol (CBT) typeand any combination thereof.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein at least one of the following holds true: a. said composition is stable under pasteurization process at 57 to 68 C with a holding time of 15-30 s or a treatment of 63-65 C for 15 s or 65 C for 20 s.; b. said composition comprises about 0.5-5% Cannabis oil; c. said composition comprises an oily phase and a water phase in a ratio of about 1.5%-15% to about 98.5- 85%, respectively; d. said oily phase comprises about 4:1 to 12:1 phospholipid and said composition comprises cannabis, surfactant, carrier oil, and e. said oily phase comprises cannabis oil, egg phospholipids, soya phospholipids and wherein said water phase comprises of water.
It is also another object of the present invention to provide the composition as defined in any of the above wherein said cannabis is cannabis oil; said surfactant is phospholipids or tween 80 or any combination thereof.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein at least one of the following holds true: a. said cannabinoids are from cannabidiol (CBD) or its derivative, Tetrahydrocannabinol (THC) or its derivative, and any combination of that; b. final concentration of mentioned THC or its derivative, in the emulsion is 80- 100 mg/ml; c. a single dose of about 0.5 ml of cannabis emulsion contains a dose of about 12 to about 15 mg THC; d. the ratio of mentioned oily fraction and mentioned phospholipid is between 4:1 and 12:1; e. mentioned oily fraction is 5%- 50%; and f. said oily fraction is in the range of about 1.5-15%.
It is also another object of the present invention to provide the composition as defined in any of the above, wherein at least one of the following is true: a. mentioned oily fraction is from cannabis oil, borage oil, coconut oil, cottonseed oil, soybean oil, safflower oil, sunflower oil, corn oil, olive oil, palm oil, peanut oil, canola oil, and any combination thereof; b.
mentioned phospholipids, or its derivatives are derived from a naturally originated food sources from soya , rapeseed, sunflower, cattle milk, fish eggs, poultry eggs and any combination of that;
c. said phospholipids, or derivative thereof, are produced by a synthetic route; d. said composition is stable under pasteurization process at 57 to 68 C with a holding time of 15-30 s or a treatment of 63-65 C for 15 s or 65 C for 20 s It is also another object of the present invention to provide the composition as defined in any of the above claims, wherein said composition is prepared by the steps of: a.
combining phospholipids or its derivatives and an oily fraction and obtaining an oily phase; b. mixing oily and water phases in an ultrasonicator and obtaining pre-emulsion; and c. transferring pre-emulsion into a ultrasonicator and obtaining a cannabis composition in the formulation of an emulsion; further wherein said oily fraction contains about 0.5-5% cannabinoids.
It is also another object of the present invention to provide the composition as defined in any of the above, further prepared by steps of: a. preparing an oil phase by mixing cannabis oil, soya phospholipids, polysorbate 80 and Lecithin; b. preparing a water phase c.
adding the water phase to the oil phase d. preparation of an emulsion from said mixture of step c with Ultrasonicator at 90% amplitude for 20 min in a cold-water bath or in a reaction chamber with a cooling jacket; e.
optionally, sterilizing produced emulsion.
It is also another object of the present invention to provide the use as defined in any of the above claims in which composition comprises small-size particles in a diameter less than 200 nm and preferably <50nm ( Passing through 0.2 ilm=200nm filter), It is also another object of the present invention to provide the use as defined in any of the above, wherein said composition comprises about 0.5-5% cannabis oil.
It is also another object of the present invention to provide the use as defined in any of the above, wherein said a. the composition is administered in a manner selected from the group consisting of:
sublingual, transdermal, oromucosal, rectal, Vaginal, oral, topical and any combination thereof. b.
The composition is formulated in a dosage form from oral, pill, capsule, powder or liquid or solid, pastes, syrup, topical, cream, gel, lotion, ointment, drops, skin patch, vaginal, and any combination of that.
It is also an object of the present invention to provide the composition as mentioned above, wherein final concentration of the THC or a derivative thereof, in the emulsion is about 10-50 mg/ml.
It is also another object of the present invention to provide the composition as mentioned above, wherein a single dose of about 0.5 ml of the cannabis emulsion contains a dose of about 10 mg THC.
It is also another object of the present invention to provide the composition as mentioned above, wherein the ratio of the oily fraction and the phospholipid is between 4:1 and 12:1.
It is also an object of the present invention to provide the composition as mentioned above, wherein the oily fraction is in the range of about 1.5% to about 15%.
It is also another object of the present invention to provide the composition as mentioned above, wherein the oily fraction is selected from the group consisting of cannabis oil, coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination thereof.
It is also another object of the present invention to provide the composition as mentioned above, wherein the phospholipids or its derivatives are natural food sources like eggs, cattle milk, fish eggs, sunflower oil, soya oil, rapeseed oil, poultry and any combination of them.
It is also another object of the present invention to provide the composition as mentioned above, wherein the average particle size of the emulsion is in the range of about <50 nm.
It is also another object of the present invention to provide the composition as mentioned above, wherein the composition is stable under pasteurization process at 57 to 68 C
with a holding time of 15-30 s or a treatment of 63-65 C for 15 s or 65 C for 20 s.
It is also another object of the present invention to provide the composition as mentioned above, wherein the composition is to be administered in a route selected from a group consisting of:
transdermal, oral, topical, topical and any combination thereof.
It is also another object of the present invention to provide a composition as said above, wherein the composition is administered in a manner selected from the group consisting of: sublingual, transdermal, oromucosal, rectal, Vaginal, oral, topical and any combination thereof.
It is also another object of the present invention to provide the composition as mentioned above, wherein the composition is formulated in a dosage form liquid, solid, oral, pill, capsule, sub-lingual, orally-disintegrating, liquid solution, powder or liquid or solid , pastes, syrup, topical, cream, gel, lotion, ointment, drops, skin patch, vaginal, and any combination thereof.
It is also another object of the present invention to provide the composition as mentioned above, wherein the lipophilic solvent or suspension carrier are selected from a group consisting of long-chain triglyceride(LCT) such as coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination thereof;
It is another object of the present invention to disclose a composition prepared by combining phospholipids or its derivatives and an oily fraction for obtaining an oily phase; combining the oily phase with a water phase in an Nano emulsifier, for obtaining pre-emulsion; and transferring the pre-emulsion into a ultrasonicator for obtaining a cannabis composition in the formulation of an emulsion in which the oily fraction contains about 0.5-5% cannabinoids.
It is also another object of the present invention to provide the preparation method as mentioned above in which the cannabinoids are from: Cannabidiol (CBD) type or its derivatives or A9-Tetrahydrocannabinol (THC) type or its derivatives It is also an object of the present invention to provide the preparation method as mentioned above, wherein final concentration of the THC or a derivative thereof, in the emulsion is about 5-50 mg/ml.
It is also another object of the present invention to provide the preparation method as mentioned above in which a single dose of about 0.5 ml the cannabis emulsion contains a dose of about 10 mg THC.
It is also another object of the present invention to provide the preparation method as mentioned above in which the ratio of the oily fraction and the phospholipid is between 8:1 and 12:1.
It is also another object of the present invention to provide the preparation method as mentioned above for providing the composition with oily fraction in the range of 5%-50%.
It is also another object of the present invention to provide the preparation method as mentioned above, wherein the step uses a Ultra sonic Nano emulsifier having a power of 100-3000 W and 90% amplitude for 30 min, thereby resulting in an average particle size of the emulsion in the range of about <50 nm.
It is also another object of the present invention to provide the preparation method as mentioned above for sterilizing the cannabis composition.
It is also another object of the present invention to provide the preparation method as mentioned above, additionally comprising steps of formulating the composition to be stable under pasteurization process at 57 to 68 C with a holding time of 15-30 s or a treatment of 63-65 C for 15 s or 65 C for 20 s.
It is also another object of the present invention to provide the preparation method as mentioned above, additionally comprising steps of formulating the cannabis composition is administered in a manner selected from the group consisting of: sublingual, transdermal, oromucosal, rectal, Vaginal, oral, topical and any combination thereof.
It is also another object of the present invention to provide the preparation method as mentioned above, additionally comprising steps of formulating the cannabis composition is formulated in a dosage form selected from the group consisting of liquid, solid, oral, pill, capsule, sub-lingual, orally-disintegrating, liquid solution, powder or liquid or solid , pastes, syrup, topical, cream, gel, lotion, ointment, drops, skin patch, vaginal, and any combination thereof.
It is also another object of the present invention to provide the preparation method as mentioned above in which the oily fraction is cannabis oil obtained from a cannabis plant.
It is also another object of the present invention to provide the preparation method as mentioned above for formulating the cannabis composition for administration of about 5 mg- 15 mg THC per dosage unit.
It is also another object of the present invention to provide the preparation method as mentioned above for formulating the cannabis composition to contain an additional lipophilic solvent or suspension carrier.
It is also another object of the present invention to disclose the aforementioned method, wherein the cannabinoids are from: Cannabidiol (CBD) type or its derivatives or A9-Tetrahydrocannabinol (THC) type r its derivatives.
It is also another object of the present invention to disclose the aforementioned method for administering the composition with a final concentration of the THC or a derivative of that, in the emulsion of about 10 mg/ml.
It is also another object of the present invention to disclose the aforementioned method for administering the composition in a single dose of about 0.5 ml the cannabis emulsion containing a dose of about 10 mg THC.
It is also another object of the present invention to disclose the aforementioned method, additionally comprising steps of providing the composition with oily fraction is in the range of about 1.5% to about 15%.
It is also another object of the present invention to disclose the aforementioned method for providing the composition with oily fraction is in the range of about 10%-30%.
It is also another object of the present invention to disclose the aforementioned method for providing the composition wherein the oily fraction is from cannabis oil, coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination thereof.
It is also another object of the present invention to disclose the aforementioned method in which the phospholipids or its derivatives are derived from a natural food sources from poultry eggs, soya, rapeseed, sunflower, cattle milk, fish eggs and any combination thereof.
It is also another object of the present invention to disclose the aforementioned method in which the phospholipids, or its derivatives are derived by a synthetic route.
It is also another object of the present invention to disclose the aforementioned method, wherein the average particle size of the emulsion is in the range of about <50 nm.
It is also another object of the present invention to disclose the aforementioned method for administering the composition in the following manner: sublingual, transdermal, oromucosal, rectal, Vaginal, oral, topical and any combination of that.
It is also an object of the present invention to disclose the aforementioned method for administering the composition is formulated in a dosage form liquid, solid, oral, pill, capsule, sub-lingual, orally-disintegrating, liquid solution, powder or liquid or solid , pastes, syrup, topical, cream, gel, lotion, ointment, drops, skin patch, vaginal, and any combination thereof.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
It is understood that other examples may be used and structural changes may be made in within the scope of the present invention. The present invention may be performed according to the claims without some or all of these specific details.
The principle of the present invention is to provide a composition containing oil and phospholipids as an emulsion and useful for human, having used an oily fraction containing about 0.5-15%
cannabinoids. Such cannabinoids may be either cannabidiol (CBD) and/or Tetrahydrocannabinol (THC) or an extract of them. More specifically the present invention declaims a composition containing cannabinoids enhanced emulsions for either topical or oral use.
The term "cannabidiol (CBD)" refers to cannabinoids identified in cannabis.
The term "Tetrahydrocannabinol (THC)" refers to the principal psychoactive cannabinoid of the cannabis plant.
The term "particle size" refers to oil in water droplet diameter, or water in oil droplet diameter, in an emulsion.
The term "room temperature" refers to 20-25 Celsius degrees.
The term "fridge temperature" refers to 2-8 Celsius degrees.
The term "stable" refers to the stability of the emulsion.
It is another object of the present invention to disclose a cannabis emulsion composition containing phospholipids or its derivatives and an oily fraction, wherein the oily fraction is enriched and contains about 0.5-5% cannabinoids. Such cannabinoids may be from cannabidiol (CBD) or its derivative, Tetrahydrocannabinol (THC) or its derivative, and any combination of them.
In preferred embodiments, the Nano emulsion composition is provided with a lower viscosity.
In preferred embodiments, the Nano-emulsion composition is useful for transferring variety of molecules specifically fatty molecules, without sediments or any solid particles.
In preferred embodiments, the final concentration of THC or its derivative in the emulsion is 5-50 mg/ml. Thus, a 0.5 ml dose of the cannabis emulsion, contains a dose of about 10 mg THC.
It is in the scope of this invention to provide a composition as defined in any of the above claims in which the ratio of the oily fraction and the phospholipid is between 4:1 and 12:1.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the oily fraction is in the range of about 5% to about 15%.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the oily fraction may be from the group consisting of cannabis oil coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination of them.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the phospholipids are from natural food sources such as, poultry eggs, soya, rapeseed, sunflower, cattle milk, fish eggs and any combination thereof. In other embodiments, the phospholipids, or derivative of that have a synthetic route.
The composition as provided in the present invention may be manufactured to provide emulsion particle sizes in the range of about <50 nm. Such particularly small particle size is achieved through using a ultrasonicator having a power of 100-3000 Wats, 90% amplitude.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the composition is for oral administration in a formulation selected from a group of preparations consisting of syrup, drops, solution, suspension, tablet, capsule and any combination thereof.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the composition is for topical administration from the following ways: cream, ointment lotion, foam, transdermal patch and any combination thereof.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the composition is formulated for administration of 5 mg-15 mg THC per dosage unit.
It is further in the scope of this invention to provide additional lipophilic solvent or suspension carrier, which may be in a non-limiting example, long-chain triglyceride(LCT) such as coconut oil, soybean oil, sunflower oil, olive oil, palm oil, peppermint oil, poppy seed oil, canola oil, hydrogenated soybean oil, hydrogenated vegetable oils, glyceryl esters of saturated fatty acids or any combination of them;
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the THC or its derivative is from THC or its derivatives and any combination of that.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the THC or its derivatives is extracted from cannabis.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the composition contains least one additional cannabinoid or a derivative of that.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the Cannabidiol (CBD) or a derivative of that is from CBD or its derivatives and any combination of them.
It is further in the scope of this invention to provide a composition as defined in any of the above claims in which the CBD or its derivatives are extracted from cannabis.
In order to understand the invention and to see how it may be implemented in practice, a number of preferred examples which is not limited to these examples will now be described:
Example 1 Proposed Emulsion Composition: Cannabis oil :2g; Egg phospholipid: 3g;
Polysorbate80: 3g;
Soya oil: 3g; Purified water up to 100m1 Equipment: A Ultrasonicate device set on Amplitude: 90% with 400W power for 20 min.
Example 2 Protocol for Preparation of Cannabis Emulsion Emulsion Composition: Cannabis oil compositions containing THC and CBD in predetermined ratios; Surfactant: phospholipids and/or tween 80 and/or others; Lecithin;
Purified water Manufacturing Flow Chart:
Pre-Emulsion: Generating a Pre-Emulsion containing Oily and Water phases.
Nano-Emulsion: The resulting Pre-Emulsion is then undergone ultrasonication process in order to create a Nano-Emulsion;
Sterilization and confirmation of Nano sized particle: The resulting Nano-Emulsion is then passed through a 0.2 p,m filter resulting in the Sterilization of the Emulsion which confirms Nano size of the product (Filter pore size is 200 nm).
,
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3065074A CA3065074A1 (en) | 2019-12-13 | 2019-12-13 | Producing water soluble nano-emulsion particles containing cannabis/ cannabinoid oil or cannabis concentrate using ultrasonic processing technology and its use thereof in the beverage, edible powder and multipurpose cream |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3065074A CA3065074A1 (en) | 2019-12-13 | 2019-12-13 | Producing water soluble nano-emulsion particles containing cannabis/ cannabinoid oil or cannabis concentrate using ultrasonic processing technology and its use thereof in the beverage, edible powder and multipurpose cream |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3065074A1 true CA3065074A1 (en) | 2021-06-13 |
Family
ID=76433072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3065074A Abandoned CA3065074A1 (en) | 2019-12-13 | 2019-12-13 | Producing water soluble nano-emulsion particles containing cannabis/ cannabinoid oil or cannabis concentrate using ultrasonic processing technology and its use thereof in the beverage, edible powder and multipurpose cream |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA3065074A1 (en) |
-
2019
- 2019-12-13 CA CA3065074A patent/CA3065074A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11819491B2 (en) | Dilutable formulations of cannabinoids and processes for their preparation | |
| US10285971B2 (en) | Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same | |
| CN103037708B (en) | Nanoemulsion including sucrose fatty acid ester | |
| CN103190631B (en) | Non-aqueous pre-emulsion composition and preparation comprise the method for the beverage of phytosterol | |
| AU2014235283B2 (en) | Formulations of water-soluble derivatives of vitamin E and compositions containing same | |
| CN107080734A (en) | The emulsion of PEG derivatives comprising tocopherol | |
| US20160081975A1 (en) | Soft gel compositions and pre-gel concentrates | |
| BRPI0617406B1 (en) | Microemulsions for use in food and beverage products, method of making them, concentrate and food or beverage composition | |
| JP6282645B2 (en) | Racecadotril lipid composition | |
| TWI531318B (en) | Microemulsion preconcentrates and microemulsions, and preparation processes of the same | |
| US10071030B2 (en) | Carrier comprising non-neutralised tocopheryl phosphate | |
| WO2008101344A1 (en) | Soluble bioactive lipophilic compounds compositions | |
| CA3065074A1 (en) | Producing water soluble nano-emulsion particles containing cannabis/ cannabinoid oil or cannabis concentrate using ultrasonic processing technology and its use thereof in the beverage, edible powder and multipurpose cream | |
| JP6622950B1 (en) | Compositions for preparing microemulsions, microemulsions, methods for their production and use of microemulsions | |
| CN104720070A (en) | Microemulsion pre-concentrated material, microemulsion, and preparation method of microemulsion pre-concentrated material and microemulsion | |
| Garti et al. | Improved solubilization and bioavailability of nutraceuticals in nanosized self‐assembled liquid vehicles | |
| TW200408633A (en) | Aqueous solution of ascorbic acid and method for producing same | |
| JP2003160477A (en) | Aqueous composition of higher aliphatic alcohol, production method and administration method | |
| Garti | 11 Cosmetoceuticals in |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220906 |
|
| FZDE | Discontinued |
Effective date: 20220906 |